03:06 AM EDT, 10/27/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) updated the expected data readout timing for the late-stage Pacific-9 study to the first half of 2027 from the previous second half of 2026 schedule, according to a Tuesday release. The AstraZeneca-led trial is evaluating durvalumab plus monalizumab or oleclumab as a treatment for unresectable stage 3 non-small cell lung cancer that has not yet progressed after platinum-based chemoradiation therapy. Innate Pharma (IPH.PA) and AstraZeneca are jointly developing monalizumab. The Paris-listed biotechnology company said the delay was due to the event-driven nature of the study.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.